EUVIMEDEUVIMED entdecken
Open Access

Evaluation of Plasmapheresis vs Immunoglobulin as First Treatment After Ineffective Systemic Corticosteroid Therapy for Patients With Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis

Yuki Miyamoto, Hiroyuki Ohbe, Ryosuke Kumazawa, Hiroki Matsui, Kiyohide Fushimi, Hideo Yasunaga, Bon Ohta

JAMA Dermatology · 2023

DOI: 10.1001/jamadermatol.2023.0035 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JAMA Dermatology, 2023. Verfasst von Yuki Miyamoto und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Emergency Medicine, Kyoto Prefectural University of Medicine, Kyoto, Japan. Hauptthemen laut MEDLINE: Immunoglobulins, Intravenous, Stevens-Johnson Syndrome. Die Arbeit wurde bisher 30-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance Stevens-Johnson syndrome and toxic epidermal necrolysis (SJS/TEN) are severe cutaneous adverse reactions, and patients with SJS/TEN frequently require intensive care. However, there is limited evidence on the clinical outcomes of immunomodulating therapy, including plasmapheresis and intravenous immunoglobulin (IVIG) in patients with SJS/TEN.

Objective

To compare clinical outcomes of patients with SJS/TEN who were treated with plasmapheresis first vs IVIG first after ineffective systemic corticosteroid therapy. Design, Setting, and Participants This retrospective cohort study used data from a national administrative claims database in Japan that included more than 1200 hospitals and was conducted from July 2010 to March 2019. Inpatients with SJS/TEN who received plasmapheresis and/or IVIG therapy after initiation of at least 1000 mg/d of methylprednisolone equivalent systemic corticosteroid therapy within 3 days of hospitalization were included. Data were analyzed from October 2020 to May 2021. Exposures Patients who received IVIG or plasmapheresis therapy within 5 days after initiation of systemic corticosteroid therapy were included in the IVIG- and plasmapheresis-first groups, respectively. Main Outcomes and Measures In-hospital mortality, length of hospital stay, and medical costs.

Results

Of 1215 patients with SJS/TEN who had received at least 1000 mg/d of methylprednisolone equivalent within 3 days of hospitalization, 53 and 213 patients (mean [SD] age, 56.7 [20.2] years; 152 [57.1%] women) were included in the plasmapheresis- and IVIG-first groups, respectively. Propensity-score overlap weighting showed no significant difference in inpatient mortality rates between the plasmapheresis- and IVIG-first groups (18.3% vs 19.5%; odds ratio, 0.93; 95% CI, 0.38–2.23; P = .86). Compared with the IVIG-first group, the plasmapheresis-first group had a longer hospital stay (45.3 vs 32.8 days; difference, 12.5 days; 95% CI, 0.4–24.5 d; P = .04) and higher medical costs (US $34 262 vs $23 054; difference, US $11 207; 95% CI, $2789–$19 626; P = .009). Conclusions and Relevance This nationwide retrospective cohort study found no significant benefit to administering plasmapheresis therapy first instead of IVIG first after ineffective systemic corticosteroid treatment in patients with SJS/TEN. However, medical costs and length of hospital stay were greater for the plasmapheresis-first group.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immunoglobulins, IntravenousStevens-Johnson SyndromeHumansFemaleMiddle AgedMaleRetrospective StudiesAdrenal Cortex HormonesMethylprednisolonePlasmapheresis

Substanzen

Immunoglobulins, IntravenousAdrenal Cortex HormonesMethylprednisolone

Autor:innen und Institutionen

  • Department of Emergency Medicine, Kyoto Prefectural University of Medicine, Kyoto, Japan.
  • Department of Clinical Epidemiology and Health Economics, School of Public Health, The University of Tokyo, Tokyo, Japan.
  • Department of Health Policy and Informatics, Tokyo Medical and Dental University Graduate School of Medicine, Tokyo, Japan.

Zitieren

APA

Miyamoto, Y., Ohbe, H., Kumazawa, R., Matsui, H., Fushimi, K., Yasunaga, H., & Ohta, B. (2023). Evaluation of Plasmapheresis vs Immunoglobulin as First Treatment After Ineffective Systemic Corticosteroid Therapy for Patients With Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis. JAMA Dermatology. https://doi.org/10.1001/jamadermatol.2023.0035

Vancouver

Miyamoto Y, Ohbe H, Kumazawa R, Matsui H, Fushimi K, Yasunaga H, et al. Evaluation of Plasmapheresis vs Immunoglobulin as First Treatment After Ineffective Systemic Corticosteroid Therapy for Patients With Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis. JAMA Dermatology. 2023. doi:10.1001/jamadermatol.2023.0035

BibTeX
@article{Miyamoto2023,
  author = {Miyamoto, Yuki and Ohbe, Hiroyuki and Kumazawa, Ryosuke and Matsui, Hiroki and Fushimi, Kiyohide and Yasunaga, Hideo and Ohta, Bon},
  title = {Evaluation of Plasmapheresis vs Immunoglobulin as First Treatment After Ineffective Systemic Corticosteroid Therapy for Patients With Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis},
  journal = {JAMA Dermatology},
  year = {2023},
  doi = {10.1001/jamadermatol.2023.0035}
}
Kostenlos starten →